Discovery of Novel Small Molecule Activators of β-Catenin Signaling

por Verkaar, Folkert, van der Stelt, Mario, Blankesteijn, W. Matthijs, van der Doelen, Antoon A., Zaman, Guido J. R.
Publicado 2011

Amino Acid-Metabolizing Enzymes in Advanced High-Grade Serous Ovarian Cancer Patients: Value of Ascites as Biomarker Source and Role for IL4I1 and IDO1

por Grobben, Yvonne, den Ouden, Judith E., Aguado, Cristina, van Altena, Anne M., Kraneveld, Aletta D., Zaman, Guido J. R.
Publicado 2023

Comparative biochemical kinase activity analysis identifies rivoceranib as a highly selective VEGFR2 inhibitor

por Jang, Seong, Strickland, Bill, Finis, Lynda, Kooijman, Jeffrey J., Melis, Janneke J. T. M., Zaman, Guido J. R., Van Tornout, Jan
Publicado 2023

Structural insights into human Arginase-1 pH dependence and its inhibition by the small molecule inhibitor CB-1158

por Grobben, Yvonne, Uitdehaag, Joost C.M., Willemsen-Seegers, Nicole, Tabak, Werner W.A., de Man, Jos, Buijsman, Rogier C., Zaman, Guido J.R.
Publicado 2019

Quantitative proteomic and phosphoproteomic comparison of human colon cancer DLD-1 cells differing in ploidy and chromosome stability

por Viganó, Cristina, von Schubert, Conrad, Ahrné, Erik, Schmidt, Alexander, Lorber, Thomas, Bubendorf, Lukas, De Vetter, Judith R. F., Zaman, Guido J. R., Storchova, Zuzana, Nigg, Erich A.
Publicado 2018

Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitors

por Conlon, Neil T., Kooijman, Jeffrey J., van Gerwen, Suzanne J. C., Mulder, Winfried R., Zaman, Guido J. R., Diala, Irmina, Eli, Lisa D., Lalani, Alshad S., Crown, John, Collins, Denis M.
Publicado 2021

Comparison of the Cancer Gene Targeting and Biochemical Selectivities of All Targeted Kinase Inhibitors Approved for Clinical Use

por Uitdehaag, Joost C. M., de Roos, Jeroen A. D. M., van Doornmalen, Antoon M., Prinsen, Martine B. W., de Man, Jos, Tanizawa, Yoshinori, Kawase, Yusuke, Yoshino, Kohichiro, Buijsman, Rogier C., Zaman, Guido J. R.
Publicado 2014

Chemotherapy sensitivity testing on ovarian cancer cells isolated from malignant ascites

por den Ouden, Judith E., Zaman, Guido J.R., Dylus, Jelle, van Doornmalen, Antoon M., Mulder, Winfried R., Grobben, Yvonne, van Riel, Wilhelmina E., de Hullu, Joanne A., Buijsman, Rogier C., van Altena, Anne M.
Publicado 2020

Selective Targeting of CTNNB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing Drugs

por Uitdehaag, Joost C. M., de Roos, Jeroen A. D. M., van Doornmalen, Antoon M., Prinsen, Martine B. W., Spijkers-Hagelstein, Jill A. P., de Vetter, Judith R. F., de Man, Jos, Buijsman, Rogier C., Zaman, Guido J. R.
Publicado 2015

Phosphoproteomic profiling of T cell acute lymphoblastic leukemia reveals targetable kinases and combination treatment strategies

por Cordo’, Valentina, Meijer, Mariska T., Hagelaar, Rico, de Goeij-de Haas, Richard R., Poort, Vera M., Henneman, Alex A., Piersma, Sander R., Pham, Thang V., Oshima, Koichi, Ferrando, Adolfo A., Zaman, Guido J. R., Jimenez, Connie R., Meijerink, Jules P. P.
Publicado 2022

Stable aneuploid tumors cells are more sensitive to TTK inhibition than chromosomally unstable cell lines

por Libouban, Marion A.A., de Roos, Jeroen A.D.M., Uitdehaag, Joost C.M., Willemsen-Seegers, Nicole, Mainardi, Sara, Dylus, Jelle, de Man, Jos, Tops, Bastiaan, Meijerink, Jules P.P., Storchová, Zuzana, Buijsman, Rogier C., Medema, René H., Zaman, Guido J.R.
Publicado 2017

Comparative kinase and cancer cell panel profiling of kinase inhibitors approved for clinical use from 2018 to 2020

por Kooijman, Jeffrey J., van Riel, Wilhelmina E., Dylus, Jelle, Prinsen, Martine B. W., Grobben, Yvonne, de Bitter, Tessa J. J., van Doornmalen, Antoon M., Melis, Janneke J. T. M., Uitdehaag, Joost C. M., Narumi, Yugo, Kawase, Yusuke, de Roos, Jeroen A. D. M., Willemsen-Seegers, Nicole, Zaman, Guido J. R.
Publicado 2022

IL-7 Receptor Mutations and Steroid Resistance in Pediatric T cell Acute Lymphoblastic Leukemia: A Genome Sequencing Study

por Li, Yunlei, Buijs-Gladdines, Jessica G. C. A. M., Canté-Barrett, Kirsten, Stubbs, Andrew P., Vroegindeweij, Eric M., Smits, Willem K., van Marion, Ronald, Dinjens, Winand N. M., Horstmann, Martin, Kuiper, Roland P., Buijsman, Rogier C., Zaman, Guido J. R., van der Spek, Peter J., Pieters, Rob, Meijerink, Jules P. P.
Publicado 2016

Pharmacological validation of TDO as a target for Parkinson’s disease

por Perez‐Pardo, Paula, Grobben, Yvonne, Willemsen‐Seegers, Nicole, Hartog, Mitch, Tutone, Michaela, Muller, Michelle, Adolfs, Youri, Pasterkamp, Ronald Jeroen, Vu‐Pham, Diep, van Doornmalen, Antoon M., van Cauter, Freek, de Wit, Joeri, Gerard Sterrenburg, Jan, Uitdehaag, Joost C.M., de Man, Jos, Buijsman, Rogier C., Zaman, Guido J.R., Kraneveld, Aletta D.
Publicado 2021

Targeting Indoleamine 2,3-Dioxygenase in Cancer Models Using the Novel Small Molecule Inhibitor NTRC 3883-0

por Grobben, Yvonne, de Man, Jos, van Doornmalen, Antoon M., Muller, Michelle, Willemsen-Seegers, Nicole, Vu-Pham, Diep, Mulder, Winfried R., Prinsen, Martine B. W., de Wit, Joeri, Sterrenburg, Jan Gerard, van Cauter, Freek, den Ouden, Judith E., van Altena, Anne M., Massuger, Leon F., Uitdehaag, Joost C. M., Buijsman, Rogier C., Zaman, Guido J. R.
Publicado 2021